Discounts and Allowances Reserve For Discounts And Allowances [Member] Reserve For Discounts And Allowances [Member] Accumulated Amortization and Impairments Finite-Lived Intangible Assets, Accumulated Amortization SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Amortization of intangible assets Amortization of intangible assets Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period. Statistical Measurement [Domain] Statistical Measurement [Domain] Property, plant and equipment, net Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment Restricted cash Restricted Cash, Current Award Timing Predetermined Award Timing Predetermined [Flag] Gross Carrying Amount Intangible Assets, Gross (Excluding Goodwill) Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Entity File Number Entity File Number Additional Paid in Capital Additional Paid-in Capital [Member] Other Other [Member] Other OTHER EXPENSE, NET Other Income and Other Expense Disclosure [Text Block] Tabular List, Table Tabular List [Table Text Block] Customer, Top Ten Products Customer, Top Ten Products [Member] Customer, Top Ten Products Adoption of New Accounting Standards and Recently Issued Accounting Standards, Not Adopted New Accounting Pronouncements, Policy [Policy Text Block] SOFR, EURIBOR, and SONIA Rate Secured Overnight Financing (SOFR) Rate, EURIBOR, And Sterling Overnight Index Average (SONIA) Rate [Member] Secured Overnight Financing (SOFR) Rate, EURIBOR, And Sterling Overnight Index Average (SONIA) Rate Vyzulta® Infringement Proceedings Vyzulta® Infringement Proceedings [Member] Vyzulta® Infringement Proceedings Proceeds from sale of assets and businesses, net of costs to sell Proceeds from Divestiture of Businesses, Net of Cash Divested Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Goodwill [Line Items] Goodwill [Line Items] Employee withholding taxes related to share-based awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Basic loss per share attributable to Bausch + Lomb Corporation (in usd per share) Basic loss per share attributable to Bausch + Lomb Corporation (in usd per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Gain (loss) recognized in Other comprehensive (loss) income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax RELATED PARTIES Related Party Transactions Disclosure [Text Block] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Total inventories Inventory, Gross Accounts payable, accrued and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Liabilities: Liabilities, Fair Value Disclosure [Abstract] REVENUE RECOGNITION Revenue from Contract with Customer [Text Block] Fair value adjustments due to changes in estimates of future payments Fair Value Adjustments [Member] Fair Value Adjustments Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] January 2031 Secured Notes Senior Secured Notes Due January 2031 [Member] Senior Secured Notes Due January 2031 Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Other comprehensive (loss) income Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Schedule of segment revenues and profit Schedule of Segment Reporting Information, by Segment [Table Text Block] Inventory Disclosure [Abstract] Measurement Input Type [Domain] Measurement Input Type [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Concentration risk percentage Concentration Risk, Percentage BHC Affiliated Entity [Member] Unamortized discounts Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Share-based compensation Share-Based Payment Arrangement, Noncash Expense Returns Reserve For Customer Returns [Member] Reserve For Customer Returns [Member] Stock options Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Product rights/patents Contractual Rights [Member] Total Bausch + Lomb Corporation shareholders’ equity Equity, Attributable to Parent Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Measurement Frequency [Axis] Measurement Frequency [Axis] Insider Trading Policies and Procedures [Line Items] Share-based compensation expense Share-Based Payment Arrangement, Expense Quarterly amortization payments Debt Instrument, Periodic Payment, Quarterly Amortization, Period One Debt Instrument, Periodic Payment, Quarterly Amortization, Period One Hedging Designation [Domain] Hedging Designation [Domain] Goodwill and Intangible Assets Disclosure [Abstract] Current assets: Assets, Current [Abstract] BHC BHC [Member] BHC Total liabilities and equity Liabilities and Equity Anti-dilutive shares not included in the computation of diluted earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Recurring basis Fair Value, Recurring [Member] Pension adjustment, net of tax Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Chargebacks Reserve For Chargebacks [Member] Reserve For Chargebacks [Member] Cover [Abstract] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Maximum Maximum [Member] November 2025 Acquisitions November 2025 Acquisitions [Member] November 2025 Acquisitions Net income attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Accounting Policies [Abstract] Net Carrying Amount Finite-Lived Intangible Assets, Net Concentration Risk Type [Domain] Concentration Risk Type [Domain] Pharmaceuticals Pharmaceutical Products [Member] Pharmaceutical Products [Member] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Long-term debt, net of unamortized debt discount Debt Instrument [Line Items] Debt Instrument [Line Items] Acquisitions and other investments Payments to Acquire Other Investments Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Number of claims dismissed Loss Contingency, Claims Dismissed, Number Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Liabilities Liabilities [Abstract] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Depreciation and amortization of intangible assets Depreciation, Depletion and Amortization, Nonproduction Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Other non-current liabilities Other Liabilities, Noncurrent Proceeds from sale of other receivables Proceeds from Sale of Other Receivables Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Product brands Product Brand [Member] Represents the rights to non-patented product brands. Goodwill impairment Goodwill, Impairment Loss Statement of Stockholders' Equity [Abstract] Operating Segment Operating Segments [Member] Loss related to settlements Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss) Related To Settlement Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss) Related To Settlement Less: Current portion of long-term debt Long-Term Debt, Current Maturities Statement of Cash Flows [Abstract] Company Selected Measure Amount Company Selected Measure Amount Comprehensive income attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive loss attributable to Bausch + Lomb Corporation Comprehensive Income (Loss), Net of Tax, Attributable to Parent Measurement Input Type [Axis] Measurement Input Type [Axis] Allowance for Credit Losses Receivables, Trade And Other Accounts Receivable, Allowance For Doubtful Accounts, Policy 1 [Policy Text Block] Receivables, Trade And Other Accounts Receivable, Allowance For Doubtful Accounts, Policy 1 Name Measure Name Letter of Credit Letter of Credit [Member] Secured Debt Secured Debt [Member] Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Deferred tax liabilities, net Deferred Income Tax Liabilities, Net Document Fiscal Period Focus Document Fiscal Period Focus Award Timing Method Award Timing Method [Text Block] Litigation Case [Domain] Litigation Case [Domain] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Award Type [Axis] Award Type [Axis] Foreign currency translation adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Hedging Relationship [Domain] Hedging Relationship [Domain] Total long-term debt and other Long-term debt issued and outstanding Long-Term Debt PSUs/RSUs Performance Restricted Share Units And Restricted Stock Units [Member] Performance Restricted Share Units And Restricted Stock Units Legal Entity [Axis] Legal Entity [Axis] Total assets Assets 2027 Finite-Lived Intangible Asset, Expected Amortization, Year One Trading Symbol Trading Symbol Geographical [Domain] Geographical [Domain] Common shares issued under share-based compensation plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Pharmaceuticals Pharmaceuticals [Member] Pharmaceuticals Entity Address, City or Town Entity Address, City or Town Cash Flows From Operating Activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Floor Debt Instrument, Variable Rate, Floor Debt Instrument, Variable Rate, Floor Manufacturing Equipment Manufacturing Equipment [Member] Manufacturing Equipment Effect of exchange rate changes on cash and cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Concentration Risk Type [Axis] Concentration Risk Type [Axis] INVENTORIES Inventory Disclosure [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount RSUs Restricted Stock Units (RSUs) [Member] Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Employee severance costs Severance Costs Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Rebates, Advertising Credits Portion Reserve For Rebates, Advertising Credits Portion [Member] Reserve For Rebates, Advertising Credits Portion [Member] Assets: Assets, Fair Value Disclosure [Abstract] 2030 Finite-Lived Intangible Asset, Expected Amortization, Year Four Emerging Growth Company Entity Emerging Growth Company Quebec QUEBEC 2029 Long-Term Debt, Maturity, Year Three Research and development Research and development Research and Development Expense (Excluding Acquired in Process Cost) Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Intangible assets Finite Lived and Indefinite Lived Intangible Assets [Line Items] -- None. No documentation exists for this element. -- Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Gain excluded from assessment of hedge effectiveness Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Level 2 Fair Value, Inputs, Level 2 [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Net Carrying Amount Indefinite-Lived Intangible Assets (Excluding Goodwill) Business Combination [Domain] Business Combination [Domain] October 2028 Secured Notes Senior Secured Notes Due October 2028 [Member] Senior Secured Notes Due October 2028 Common shares, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Provision Accounts Receivable, Credit Loss Expense (Reversal) Current period provision SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account TSR PSUs TSR Performance-Based Restricted Stock Units [Member] TSR Performance-Based Restricted Stock Units [Member] Plan Name [Axis] Plan Name [Axis] PEO PEO [Member] Number of lawsuits pending Loss Contingency, Pending Claims, Number May 2027 Term Facility and September 2028 Term Facility Term Loan Due January 2031 And Term Loan Due September 2028 [Member] Term Loan Due January 2031 And Term Loan Due September 2028 Non-cash Investing Activities Noncash Investing and Financing Items [Abstract] Interest income Investment Income, Interest Foreign exchange loss Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Schedule of estimated aggregate amortization expense for each of the five succeeding years Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Accumulated Deficit Retained Earnings [Member] Prepaid expenses and other current assets (Note 4) Prepaid expenses and other current assets, related party Prepaid Expense and Other Assets, Current Schedule of accrued and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Share-Based Payment Arrangement [Abstract] Cash and cash equivalents and restricted cash, beginning of period Cash and cash equivalents and restricted cash, end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Variable rate Debt Instrument, Basis Spread on Variable Rate Purchases of marketable securities Payments to Acquire Marketable Securities Interest expense Interest Expense [Member] Nonrecurring Fair Value, Nonrecurring [Member] Intangible assets, net Net Carrying Amount Intangible Assets, Net (Excluding Goodwill) Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Product and Service [Domain] Product and Service [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Hedging Relationship [Axis] Hedging Relationship [Axis] Antidilutive securities excluded from computation of earnings per share, treasury stock method, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Treasury Stock Method, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Treasury Stock Method, Amount Bausch + Lomb Corporation Shareholders’ Equity Parent [Member] Net loss Net loss Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Asset Acquisition and Business Combination [Table] Business Combination [Table] Aggregate notional amounts Derivative, Notional Amount Organization, Consolidation and Presentation of Financial Statements [Abstract] Other Income and Expenses [Abstract] Schedule of fair values of assets acquired and liabilities assumed Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Acquisitions (Note 5) Goodwill, Acquired During Period SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Proceeds from exercise of stock options Proceeds from Stock Options Exercised City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Litigation and other matters Gain (Loss) from Litigation Settlement Accrued and other current liabilities Accrued and other current liabilities Accrued Liabilities, Current Revenues Revenues Net [Member] Aggregate net revenues during the period in the normal course of business. Commitments and Contingencies Disclosure [Abstract] Lumify Paragraph IV Proceedings Slayback ANDA Litigation Lumify Paragraph IV Proceedings Slayback ANDA Litigation [Member] Lumify Paragraph IV Proceedings Slayback ANDA Litigation Cash Flows From Investing Activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash provided by (used in) operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Term (in years) Debt Instrument, Term Related Party Transactions [Abstract] Subsequent Event Subsequent Event [Member] Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Goodwill Goodwill Balance at the beginning of the period Balance at the end of the period Goodwill Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Discontinued Product Lines Discontinued Product Lines [Member] Discontinued Product Lines PEO Total Compensation Amount PEO Total Compensation Amount Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Minimum interest coverage ratio Debt Instrument, Covenant, Interest Coverage Ratio, Minimum Debt Instrument, Covenant, Interest Coverage Ratio, Minimum Remainder of 2026 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Equity Components [Axis] Equity Components [Axis] DESCRIPTION OF BUSINESS Nature of Operations [Text Block] Annual amortization rate Debt Instrument, Annual Amortization Rate, Percentage, Period One Debt Instrument, Annual Amortization Rate, Percentage, Period One Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Product sales Product [Member] Fair value, contingent consideration obligations, discount rate Business Combination, Contingent Consideration, Liability, Measurement Input Number of reportable segments Number of Reportable Segments RSUs, PSUs and Stock options Employee Stock Options, Restricted Stock Units, And Performance-Based Restricted Stock Units [Member] Employee Stock Options, Restricted Stock Units, And Performance-Based Restricted Stock Units Unrecognized tax benefits including interest and penalties Unrecognized Tax Benefits, Including Interest And Penalties The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date. Related party transaction, term Related Party Transaction, Term Of Agreement Related Party Transaction, Term Of Agreement Entity Address, Country Entity Address, Country Other Performance Measure, Amount Other Performance Measure, Amount Stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Address, State or Province Entity Address, State or Province Allowances for losses on trade receivables and inventories Allowances For Losses On Accounts Receivable And Inventories Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions. Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Related Party, Type [Domain] Related and Nonrelated Parties [Domain] Total current liabilities Liabilities, Current Litigation Status [Axis] Litigation Status [Axis] Derivative Instrument [Axis] Derivative Instrument [Axis] Individual: Individual [Axis] Minimum aggregate amount of loans outstanding of total commitments, percent Debt Instrument, Covenant, Minimum Aggregate Amount Of Loans Outstanding Of Total Commitments, Percent Debt Instrument, Covenant, Minimum Aggregate Amount Of Loans Outstanding Of Total Commitments, Percent Research and development expenses Research and Development Expense [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Entity [Domain] Entity [Domain] Bausch Health Americas Bausch Health Americas [Member] Bausch Health Americas Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Number of innovative therapies Number Of Innovative Therapies Number Of Innovative Therapies Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Document Fiscal Year Focus Document Fiscal Year Focus Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Employee Compensation and Benefit Costs Accrued Employee Benefits, Current Repayments of debt Repayments of Long-Term Debt Entity Interactive Data Current Entity Interactive Data Current Plan Name [Domain] Plan Name [Domain] Acquisition-related costs Business Combination, Acquisition-Related Cost, Expense May 2027 Revolving Credit Facility Revolving Credit Facility Due May 2027 [Member] Revolving Credit Facility Due May 2027 Weighted average service period over which compensation cost is expected to be recognized (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition LEGAL PROCEEDINGS Legal Matters and Contingencies [Text Block] Interest settlements from cross-currency swaps Proceeds from Derivative Instrument, Investing Activities Share-based payment award, number of additional shares authorized (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Additional Shares, Authorization Pending Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Additional Shares, Authorization Pending Valuation allowance against deferred tax assets Deferred Tax Assets, Valuation Allowance Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Business Combination, Contingent Consideration, Type [Axis] Business Combination, Contingent Consideration, Type [Axis] Schedule of share-based awards granted Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Goodwill [Table] Goodwill [Table] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] B&L Trademark Trademarks [Member] Increase (Decrease) in Shareholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Ownership [Domain] Ownership [Domain] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability ACCUMULATED OTHER COMPREHENSIVE LOSS Comprehensive Income (Loss) Note [Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Selling, general and administrative (Note 4) Charges incurred, separation agreement with BHC Selling, general and administrative Selling, General and Administrative Expense Reserve beginning balance Reserve ending balance Cooperative advertising credits included in rebates SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Deferred tax assets, net Deferred Income Tax Assets, Net Schedule of the components of accumulated other comprehensive loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Whitecap Biosciences Acquisition Whitecap Biosciences Acquisition [Member] Whitecap Biosciences Acquisition Other non-current assets (Note 4) Other non-current assets, related party Other Assets, Noncurrent Customer [Domain] Customer [Domain] Interest Interest Payable, Current Entity Central Index Key Entity Central Index Key PEO Name PEO Name Schedule of long-term debt maturities Schedule of Maturities of Long-Term Debt [Table Text Block] Gain (loss) related to changes in fair value Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Doctors Allergy Formula, LLC Litigation Doctors Allergy Formula, LLC Litigation [Member] Doctors Allergy Formula, LLC Litigation [Member] Accrued and other current liabilities Accrued Liabilities, Current [Member] Accrued Liabilities, Current Finished goods Inventory, Finished Goods, Gross Cross-currency swaps Currency Swap [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Revolving Credit Facility Revolving Credit Facility [Member] Balance, as of January 1, Balance, as of March 31, Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Non-current portion Business Combination, Contingent Consideration, Liability, Noncurrent Arrangement Duration Trading Arrangement Duration Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Percentage of shares held Sale of Stock, Percentage of Ownership after Transaction Segments [Axis] Segments [Axis] Schedule of assets and liabilities associated with derivatives, included in the consolidated balance sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Measurement Input, Weighted Average Risk-Adjusted Discount Rate Measurement Input, Weighted-Average Discount Rate [Member] Measurement Input, Weighted-Average Discount Rate [Member] Exercise Price Award Exercise Price Entity Filer Category Entity Filer Category Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Thereafter Long-Term Debt, Maturity, after Year Five Subsequent Event Type [Axis] Subsequent Event Type [Axis] SHARE-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] May 2027 Incremental Term Facility Incremental Term Facility Due May 2027 [Member] Incremental Term Facility Due May 2027 Current portion included in Accrued and other current liabilities Business Combination, Contingent Consideration, Liability, Current Intangible assets, net Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Excluding Goodwill Assets Assets [Abstract] Non-current portion of long-term debt Long-Term Debt, Excluding Current Maturities Credit Facility [Axis] Credit Facility [Axis] Underlying Security Market Price Change Underlying Security Market Price Change, Percent 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Three Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Debt Instrument [Axis] Debt Instrument [Axis] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Asset Acquisition and Business Combination [Line Items] Business Combination [Line Items] Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Credit Facility [Domain] Credit Facility [Domain] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Equity Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Entity Address, Address Line One Entity Address, Address Line One Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Debt, interest rate Debt Instrument, Interest Rate, Stated Percentage Schedule of revenues by segment and product category Revenue from External Customers by Products and Services [Table Text Block] Stay of approval, period Loss Contingency, Stay Of Approval, Period Loss Contingency, Stay Of Approval, Period Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Work in process Inventory, Work in Process, Gross Ownership [Axis] Ownership [Axis] Total intangible assets Intangible Assets, Net (Excluding Goodwill) [Abstract] Branded and Other Generics Branded and Other Generic Products [Member] Branded and Other Generic Products [Member] Prepaid expenses and other current assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Fair Value as of Grant Date Award Grant Date Fair Value Entity Registrant Name Entity Registrant Name September 2028 Term Facility Term Loan Due September 2028 [Member] Term Loan Due September 2028 Surgical Surgical [Member] Surgical Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Schedule of other expense, net Schedule of Other Nonoperating Income (Expense) [Table Text Block] PSUs Performance Restricted Share Units [Member] Performance Restricted Share Units Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses Line Of Credit Facility, Percentage Of Net Cash Proceeds Of Insurance And Condemnation Proceeds From Property Or Asset Losses Payable As Mandatory Prepayments Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment. January 2031 Term Facility Term Loan Due January 2031 [Member] Term Loan Due January 2031 Diluted effect of stock options and RSUs (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Total expenses Costs and Expenses Remaining unrecognized compensation expense related to non-vested awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Related Party Transaction [Line Items] Related Party Transaction [Line Items] Shower to Shower Product Liability Litigation Shower To Shower Product Liability Litigation [Member] Shower to Shower Product Liability Litigation [Member] Document Quarterly Report Document Quarterly Report Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Number of operating segments Number of Operating Segments Acquired in-process research and development costs In-Process Research And Development Expense In-Process Research And Development Expense Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Schedule of long-term debt Schedule of Debt [Table Text Block] Number of entities after corporate restructuring Number Of Entities After Corporate Restructuring Number Of Entities After Corporate Restructuring SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Weighted-average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Related Party, Type [Axis] Related and Nonrelated Parties [Axis] Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Other non-current liabilities Other Noncurrent Liabilities [Member] Schedule of finite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Cash consideration paid Payments to Acquire Businesses, Gross Non-PEO NEO Non-PEO NEO [Member] Letters of credit outstanding Letters of Credit Outstanding, Amount Accumulated Other Comprehensive Income Loss [Table] Accumulated Other Comprehensive Income (Loss) [Table] Interest expense Interest expense Interest Expense, Debt Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments Line Of Credit Facility, Percentage Of Net Cash Proceeds From Asset Sales Outside Ordinary Course Of Business Payable As Mandatory Prepayments Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Loss) [Line Items] Other Other Intangible Assets [Member] Name Trading Arrangement, Individual Name Award Type [Domain] Award Type [Domain] Noncontrolling interest Equity, Attributable to Noncontrolling Interest Equity Awards Adjustments Equity Awards Adjustments [Member] Other Other Noncash Income (Expense) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Canada CANADA Compensation Amount Outstanding Recovery Compensation Amount Debt, principal amount Debt Instrument, Face Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Statement of Comprehensive Income [Abstract] Foreign currency exchange contracts Foreign Exchange Contract [Member] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Lumify® Paragraph IV Proceedings, Slayback ANDA Litigation Lumify® Paragraph IV Proceedings, Slayback, Somerset, Gland ANDA Litigation [Member] Lumify® Paragraph IV Proceedings, Slayback, Somerset, Gland ANDA Litigation MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Name Awards Close in Time to MNPI Disclosures, Individual Name ACCRUED AND OTHER CURRENT LIABILITIES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accretion for the time value of money Accretion For Time Value Of Money [Member] Accretion For Time Value Of Money [Member] Acquisition-related contingent consideration Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Bausch + Lomb Bausch + Lomb [Member] Bausch + Lomb Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer [Member] Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer Schedule of variable consideration provisions Summary Of Valuation And Qualifying Accounts [Table Text Block] Summary Of Valuation And Qualifying Accounts [Table Text Block] Revenues Revenues [Abstract] Patents allegedly infringed upon, number Gain Contingency, Patents Allegedly Infringed upon, Number Shower to Shower Product Liability Litigation, Atlantic County, New Jersey Multi-County, Stipulations of Dismissal Submitted Shower To Shower Product Liability Litigation, Atlantic County, New Jersey Multi-County, Stipulations Of Dismissal Submitted [Member] Shower To Shower Product Liability Litigation, Atlantic County, New Jersey Multi-County, Stipulations Of Dismissal Submitted Lotemax® SM Infringement Proceedings Lotemax® SM Infringement Proceedings [Member] Lotemax® SM Infringement Proceedings Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax 2027 Long-Term Debt, Maturity, Year One Litigation Case [Axis] Litigation Case [Axis] Segments [Domain] Segments [Domain] Damages sought Loss Contingency, Damages Sought, Value 2031 Long-Term Debt, Maturity, Year Five Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Schedule of indefinite-lived intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Remaining borrowings Line of Credit Facility, Remaining Borrowing Capacity Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Inventories Increase (Decrease) in Inventories Inventories, net Inventory, Net Amortization and write-off of debt premiums, discounts and issuance costs Amortization of Debt Issuance Costs and Discounts Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Minimum Minimum [Member] Company Selected Measure Name Company Selected Measure Name Senior Notes Senior Notes [Member] FINANCING ARRANGEMENTS Debt Disclosure [Text Block] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount June 2030 Revolving Credit Facility Revolving Credit Facility Due June 2030 [Member] Revolving Credit Facility Due June 2030 Accounts payable (Note 4) Account payable, related party Accounts Payable, Current Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] All Executive Categories All Executive Categories [Member] Common shares, no par value, unlimited shares authorized, 356,396,595 and 354,209,319 issued and outstanding at March 31, 2026 and December 31, 2025, respectively Common Stock, Value, Issued Change in the carrying amount of goodwill Goodwill [Roll Forward] Diluted weighted-average common shares (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Commitments and contingencies (Note 16) Commitments and Contingencies Deferred income taxes Deferred Income Tax Noncash Expense (Benefit) The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations. Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Business Combination [Axis] Business Combination [Axis] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Devices Device Products [Member] Device Products [Member] Smaller Reporting Company Entity Small Business Amortization of inventory step-up resulting from acquisitions Amortization Of Inventory Step Up From Acquisition Amortization Of Inventory Step Up From Acquisition Income Tax Disclosure [Abstract] Non-controlling Interest Noncontrolling Interest [Member] Document Transition Report Document Transition Report Adjusted EBITDA PSUs Adjusted EBITDA Performance Stock Units [Member] Adjusted EBITDA Performance Stock Units Underlying Securities Award Underlying Securities Amount Distribution Fees Reserve For Distribution Fees [Member] Reserve For Distribution Fees [Member] Equity Component [Domain] Equity Component [Domain] Document Period End Date Document Period End Date Gain excluded from hedge effectiveness Derivative, Gain, Excluded Component Derivative, Gain, Excluded Component PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount INCOME TAXES Income Tax Disclosure [Text Block] Proceeds from lines of credit Proceeds from Lines of Credit Acquired in-process research and development intangible asset Acquired In Process Research And Development [Member] Acquired In Process Research And Development Balance, beginning of period Balance, end of period Accounts Receivable, Allowance for Credit Loss Schedule of effect of hedging instruments on financial statements Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block] Remaining quarterly amortization payments Debt Instrument, Periodic Payment, Remaining Quarterly Amortization, Period One Debt Instrument, Periodic Payment, Remaining Quarterly Amortization, Period One Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Revenue from Contract with Customer [Abstract] Hedging Designation [Axis] Hedging Designation [Axis] Fair value of long-term debt Debt Instrument, Fair Value Disclosure Scenario [Axis] Scenario [Axis] Total equity Beginning balance Ending balance Accumulated other comprehensive loss Equity, Including Portion Attributable to Noncontrolling Interest Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table] Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table] Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company. Percentage of cash proceeds from incurrence of debt Line Of Credit Facility, Percentage Of Net Proceeds From Incurrence Of Debt Payable As Mandatory Pre-payments Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments. Document Type Document Type Level 3 Fair Value, Inputs, Level 3 [Member] LOSS PER SHARE Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Loss Contingencies [Table] Loss Contingencies [Table] Product and Service [Axis] Product and Service [Axis] Net Investment Hedging Net Investment Hedging [Member] Derivative Contract [Domain] Derivative Contract [Domain] Business Combination, Contingent Consideration, Type [Domain] Business Combination, Contingent Consideration, Type [Domain] January 2031 Refinancing Term Facility Refinancing Term Facility January 2031 [Member] Refinancing Term Facility January 2031 Total revenues Revenues Revenue from Contract with Customer, Excluding Assessed Tax Litigation Status [Domain] Litigation Status [Domain] All Individuals All Individuals [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Fair Value Disclosures [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Name Forgone Recovery, Individual Name Incentive stock plan (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] In Re: Generic Pharmaceuticals Pricing Antitrust Litigation, Pending In The U.S. District Court For The Eastern District Of Pennsylvania In Re: Generic Pharmaceuticals Pricing Antitrust Litigation, Pending In The U.S. District Court For The Eastern District Of Pennsylvania [Member] In Re: Generic Pharmaceuticals Pricing Antitrust Litigation, Pending In The U.S. District Court For The Eastern District Of Pennsylvania Weighted average interest rate Debt, Weighted Average Interest Rate Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Foreign exchange and other Goodwill, Foreign Currency Translation, Gain (Loss) Payment of employee withholding taxes related to share-based awards Payment, Tax Withholding, Share-Based Payment Arrangement Upfront payment Payments to Acquire in Process Research and Development Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Excluded from computation of earnings per share, linked to the completion of the Separation, B+L IPO, or the performance conditions not met (in shares) Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount Common shares, authorized, unlimited [Fixed List] Common Stock, Shares Authorized, Unlimited [Fixed List] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Current liabilities: Liabilities, Current [Abstract] Geographical [Axis] Geographical [Axis] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Level 1 Fair Value, Inputs, Level 1 [Member] Gain on sale of assets Gain on sale of assets Gain (Loss) on Disposition of Assets Components and classification of share-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Foreign exchange and other Gain (Loss), Foreign Currency Transaction, before Tax SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Related Party Transactions [Table] Related Party Transaction [Table] Diluted loss per share attributable to Bausch + Lomb Corporation (in usd per share) Diluted loss per share attributable to Bausch + Lomb Corporation (in usd per share) Earnings Per Share, Diluted Forecast Forecast [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Title of 12(b) Security Title of 12(b) Security British Columbia BRITISH COLUMBIA Other comprehensive income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Earnings Per Share [Abstract] Consolidation Items [Domain] Consolidation Items [Domain] Product Rebates Accrued Product Rebates, Current Represents the current portion of accrued product rebates. OTC Over the Counter Products [Member] Over the Counter Products [Member] Maximum first lien net leverage ratio Debt Instrument, Covenant, First Lien Net Leverage Ratio, Maximum Debt Instrument, Covenant, First Lien Net Leverage Ratio, Maximum 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Two Award Timing Disclosures [Line Items] Schedule of the components of inventories, net Schedule of Inventory, Current [Table Text Block] Principal Amount Long-term debt borrowings Total gross maturities Long-Term Debt, Gross Current portion of long-term debt and other financial liabilities Long-Term Debt And Secured Borrowing, Current Long-Term Debt And Secured Borrowing, Current Weighted-average exercise price (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Measurement Frequency [Domain] Measurement Frequency [Domain] ACQUISITIONS Business Combination And Asset Acquisition Disclosure [Text Block] Business Combination And Asset Acquisition Disclosure Additions (payments) of accrued legal settlements Payments for Legal Settlements Noncontrolling interest distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Corporate brands Trade Names [Member] Net loss attributable to Bausch + Lomb Corporation Net loss attributable to Bausch + Lomb Corporation Net Income (Loss) Attributable to Parent Organic Revenue Growth PSUs Organic Revenue Growth Performance-Based Restricted Stock Units [Member] Organic Revenue Growth Performance-Based Restricted Stock Units Expiration Date Trading Arrangement Expiration Date Pending Litigation Pending Litigation [Member] May 2027 Term Facility Term Loan Due May 2027 [Member] Term Loan Due May 2027 Stock options, Time-based RSUs and Performance-based RSUs Employee Stock Option, Time-Based Restricted Stock Option And Performance-Based Restricted Stock Option [Member] Employee Stock Option, Time-Based Restricted Stock Option And Performance-Based Restricted Stock Option Other Other Accrued Liabilities, Current 2031 Finite-Lived Intangible Asset, Expected Amortization, Year Five Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Payments and credits SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Property, plant and equipment, net Property, Plant and Equipment, Net Segment reporting information Segment Reporting Information [Line Items] Restructuring, integration and separation costs Restructuring Charges Adoption Date Trading Arrangement Adoption Date Base Rate Base Rate [Member] Estimated fair value of contingent consideration Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Trade receivables Increase (Decrease) in Accounts Receivable Entity Current Reporting Status Entity Current Reporting Status Customer [Axis] Customer [Axis] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Percentage of annual excess cash flow Line Of Credit Facility, Percentage Of Consolidated Excess Cash Flow Payable As Mandatory Prepayments Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans. Operating income (loss) Operating Income (Loss) Line of Credit Line of Credit [Member] Product Returns Accrued Product Returns, Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accumulated deficit Retained Earnings (Accumulated Deficit) Number of claims resolved Loss Contingency, Number of Claims Resolved Loss Contingency, Number of Claims Resolved Schedule of the components and classification of share-based compensation expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Other expense, net Other expense, net Other expense, net Other Operating Income (Expense), Net Issuance of long-term debt, net of discounts, and other financial liabilities Proceeds from Issuance of Long-Term Debt Current Fiscal Year End Date Current Fiscal Year End Date Dismissed with Prejudice Dismissed With Prejudice [Member] Dismissed With Prejudice Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag Subsequent Event Type [Domain] Subsequent Event Type [Domain] Impairment of intangible assets Impairment of Intangible Assets, Finite-Lived Finite-lived intangible assets: Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Schedule of activity in allowance for credit losses Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Payables and Accruals [Abstract] Other than stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Number of shares available for future grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Statement [Table] Statement [Table] Lumify® Paragraph IV Proceedings, Slayback, Somerset, Gland and Granules ANDA Litigation Lumify® Paragraph IV Proceedings, Slayback, Somerset, Gland and Granules ANDA Litigation [Member] Lumify® Paragraph IV Proceedings, Slayback, Somerset, Gland and Granules ANDA Litigation Derivative liabilities Net fair value Derivative Liability Adjustments to reconcile net loss to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Cash Flows From Financing Activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Dismissed For Failure To Comply With Orders Requiring Plaintiff Profile Forms Dismissed For Failure To Comply With Orders Requiring Plaintiff Profile Forms [Member] Dismissed For Failure To Comply With Orders Requiring Plaintiff Profile Forms Weighted-average grant date fair value (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Total fair value of consideration transferred Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Trade receivables, net Trade receivables, net Receivables, Net, Current Variable Rate [Domain] Variable Rate [Domain] Schedule of components and classification of financial assets and liabilities measured at fair value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Proceeds from sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Total identifiable assets Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Dilutive effect of potential common shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] All Adjustments to Compensation All Adjustments to Compensation [Member] Amendment Flag Amendment Flag Incentive stock plan, shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized 2028 Long-Term Debt, Maturity, Year Two Vision Care Vision Care [Member] Vision Care Termination Date Trading Arrangement Termination Date Net cash (used in) provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Net fair value Derivative, Fair Value, Net Unrecognized tax benefits related to interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Basic weighted-average common shares (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Indefinite-lived intangible assets: Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues Cost of Product and Service Sold Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of calculation of loss per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Number of acquisitions Business Combination, Number of Businesses Acquired Segment Reporting [Abstract] Other revenues Other Revenues [Member] Other Revenues [Member] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Debt Disclosure [Abstract] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Entity Tax Identification Number Entity Tax Identification Number Scenario [Domain] Scenario [Domain] Expenses Costs and Expenses [Abstract] Write-offs Accounts Receivable, Allowance for Credit Loss, Writeoff Current accrued loss contingencies Estimated Litigation Liability, Current Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common shares, issued (in shares) Common Stock, Shares, Issued 2030 Long-Term Debt, Maturity, Year Four Schedule of foreign exchange contracts on the consolidated statements of operations and consolidated statements of cash flows Derivatives Not Designated as Hedging Instruments [Table Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross INTANGIBLE ASSETS AND GOODWILL Goodwill and Intangible Assets Disclosure [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Additions (payments) of accrued legal settlements Proceeds from Legal Settlements First lien net leverage ratio, maximum, period two Debt Instrument, Covenant, First Lien Net Leverage Ratio, Maximum, Period Two Debt Instrument, Covenant, First Lien Net Leverage Ratio, Maximum, Period Two Schedule of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Long-term debt and other financial liabilities Long-Term Debt And Secured Borrowing, Noncurrent Long-Term Debt And Secured Borrowing, Noncurrent Loss Contingencies [Line Items] Loss Contingencies [Line Items] Acquisition-related contingent consideration adjustments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Accrued and other current liabilities Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Insider Trading Arrangements [Line Items] Corporate Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Security Exchange Name Security Exchange Name Remainder of 2026 Long-Term Debt, Maturity, Remainder of Fiscal Year Raw materials Inventory, Raw Materials, Gross Other revenues Product and Service, Other [Member] Total liabilities Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Product Concentration Risk Product Concentration Risk [Member] Accrued purchases of property, plant and equipment Capital Expenditures Incurred but Not yet Paid Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] LLT Management LLC LLT Management LLC [Member] LLT Management LLC Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] First lien net leverage ratio, maximum, period one Debt Instrument, Covenant, First Lien Net Leverage Ratio, Maximum, Period One Debt Instrument, Covenant, First Lien Net Leverage Ratio, Maximum, Period One Statement [Line Items] Statement [Line Items] Consolidation Items [Axis] Consolidation Items [Axis] Variable Rate [Axis] Variable Rate [Axis] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Rebates Reserve For Rebates [Member] Reserve For Rebates [Member] Common Shares Common Stock [Member] Milestone payment under accrued and other current liabilities Other Accrued Liabilities, Current, Milestone Payment, License Agreement Other Accrued Liabilities, Current, Milestone Payment, License Agreement Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Net decrease in cash and cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation 2022 Omnibus Incentive Plan 2022 Omnibus Incentive Plan [Member] 2022 Omnibus Incentive Plan